Price History

Hover for the daily close. The dotted line marks the period open.

Compare REVB with… →

REVB Key Statistics

As of Sep 4, 2026

Trading

Open: $1.02
Previous Close: $1.01
Day's Range: 0.99–1.04
52-Week Range: 0.88–11.60
Volume: 7.70K
Beta: −0.14

Valuation

Market Cap: $4.02M
P/E Ratio: 0.04
EPS (ttm): 27.03

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$8.91M
Profit margin: 0.00%
Shares Outstanding: 3.98M
1-Year Return: −90.98%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 44.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

REVB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+2.97%+1.49%−98.14%−92.47%−96.93%−96.38%−68.44%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−68.44%
2025	−96.38%
2024	−96.93%
2023	−92.47%
2022	−98.14%
2021	+1.49%
2020 (partial year)	+2.97%

As of September 4, 2026.

REVB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$8.91M	—
2024	$0.00	−$15.04M	—
2023	$0.00	−$120.25K	—
2022	$0.00	−$10.83M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$9.07M	−$8.91M	—
2024	$0.00	—	−$7.98M	−$15.04M	—
2023	$0.00	—	−$8.66M	−$120.25K	—
2022	$0.00	—	−$10.86M	−$10.83M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

REVB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	REVB	Biotechnology median	vs median
P/E	0.04	12.57	0.0x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Revelation Biosciences, Inc. (REVB) is capitalised at $4.02M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 8.

Over the past 52 weeks the price has ranged from $0.88 to $11.60. The most recent close on file for REVB is $1.01, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 15.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $8.91M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 27.03.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

REVB trades at a trailing price-to-earnings ratio of 0.04. That is 0 times the Biotechnology median of 12.57. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at −0.14. Annualized volatility over the trailing 5 years is 146.3%. Over the trailing twelve months the price has returned −90.98%. Measured over 5 years, that is −94.51% a year compounded.

Growth & Income

The record shows no dividend for REVB.

2026 is still running; the price is −68.44% year to date. The strongest complete calendar year on file is 2021 at +1.49%; the weakest is 2022 at −98.14%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Revelation Biosciences, Inc. (REVB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Revelation Biosciences, Inc.	REVB	$4.02M	0.0
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Revelation Biosciences, Inc. trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Visit website →

Revelation Biosciences, Inc. (REVB) Stock Analysis